According to a statement, the research will focus on developing new imaging equipment using X-rays and near-infrared (NIR) fluorescence to assist clinicians in the detection, diagnosis and treatment of cancer.
Complete surgical removal of a tumour is vital for the patient and one of the most important prognostic factors for survival. The new devices will be used in diagnostic procedures, as well as cancer surgery, to better discriminate between healthy and malignant tissue.
Cirdan Imaging’s first new device will be an imaging tool developed to assist radiologists to take a biopsy from a suspect lesion to help diagnose breast cancer. This product is expected to be launched within the next 12 months.
Queen’s University has taken an equity shareholding in Cirdan Imaging through its venture spin-out company QUBIS, representing its first-ever company spin-in.
Swiss geoengineering start-up targets methane removal
No mention whatsoever about the effect of increased methane levels/iron chloride in the ocean on the pH and chemical properties of the ocean - are we...